Producer
Dr. Reddy's Laboratories
Indian multinational pharmaceutical company (NSE: DRREDDY; HQ Hyderabad) with significant irinotecan API and finished dose manufacturing. Dr. Reddy's manufactures irinotecan hydrochloride injection for the U.S. and European generic markets — one of the leading generic irinotecan suppliers approved by FDA and EMA. The company converts camptothecin (procured primarily from Chinese botanical extraction sources) into irinotecan API via semi-synthesis at its Hyderabad API facilities. Dr. Reddy's broader oncology generics franchise includes paclitaxel, docetaxel, and topotecan, making it one of the few Indian companies with a full camptothecin-class API portfolio. Supply of irinotecan to the U.S. critical care oncology market is a significant part of the company's FDA-regulated generic pharmaceutical business.
2
Inputs supplied
2
Goods downstream
1
Facilities
0
Stories
What they make
2 inputs Dr. Reddy's Laboratories supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Dr. Reddy's Laboratories makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Global Generics (Finished Dose)
60%Pharmaceutical Services & Active Ingredients (PSAI)
25%Proprietary Products & Nutraceuticals
10%Other Businesses
5%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Concentration2024
Dr. Reddy's Laboratories, despite being an Indian company headquartered in Hyderabad, is the downstream converter in a supply chain that begins in Chinese plantations. Dr. Reddy's produces irinotecan API through semi-synthesis from camptothecin starting material sourced from China. This means that India's largest contribution to global irinotecan supply — through one of its most prominent pharmaceutical exporters — is structurally dependent on uninterrupted Chinese botanical extraction. An export restriction or licensing change on camptothecin from China (analogous to China's 2023 export controls on gallium and germanium, or its 2025 controls on rare earths) would immediately constrain Dr. Reddy's irinotecan API production, reducing the apparent diversity of global irinotecan supply to its actual Chinese botanical origin. India's role in global pharmaceutical manufacturing is often cited as a geographic diversification from China; in the camptothecin supply chain, that diversification is largely structural rather than botanical.
Dr. Reddy's Laboratories ↗Origin2023
Dr. Reddy's Laboratories was founded in 1984 in Hyderabad by Dr. Kallam Anji Reddy — a pharmaceutical scientist who had worked at Indian Drugs and Pharmaceuticals Limited (IDPL), the Indian government's bulk drug company. Dr. Reddy left IDPL specifically to demonstrate that Indian pharmaceutical companies could compete in US regulated markets, not just bulk APIs. DRL was the first Indian pharmaceutical company to successfully file a Paragraph IV ANDA (patent challenge) in the US — for ranitidine (Zantac) in 1987 — pioneering the India-to-US generics strategy that would eventually make India the world's pharmacy. Dr. Reddy's 1987 patent challenge and subsequent US approvals established the template that Sun Pharma, Cipla, Lupin, and dozens of Indian generics companies followed over the next 30 years to build India's global pharmaceuticals industry. Dr. Anji Reddy died in 2013; DRL is now run by his son-in-law G.V. Prasad.
Dr. Reddy's Laboratories ↗